Press Release

Verovaccines Receives Recommendation from EMA for Approval of VeroBlue-3, the First Member of a New Vaccine Class

Halle, Germany – March 18, 2026 – Verovaccines GmbH, a biopharmaceutical company pioneering a disruptive vaccine technology platform for animal health, today announced the **Recommendation ("Positive Opinion")** of the **European Medicines Agency (EMA) for approval of VeroBlue-3**, a vaccine against **bluetongue virus type 3**. The recommendation for approval marks a **historic milestone as VeroBlue-3 becomes the first vaccine of a new class** emerging from Verovaccines' **Unified Vaccine Platform**.

The Unified Vaccine Platform represents a breakthrough in vaccine development and production. It is based on a **common design principle**—the *antigen capsule*—which standardizes how vaccines are generated across different pathogens. This unifying concept allows Verovaccines to develop **"agile vaccines"** with exceptional speed, consistency, and cost-efficiency. The platform's modularity enables rapid adaptation to changing pathogens, regional strain variations, and emerging market needs.

The positive opinion granted for VeroBlue-3 **validates the entire vaccine class** from a regulatory perspective—covering **efficacy, safety, and quality**, vaccine construction, the development engine, manufacturability, scalability, and **GMP compliance**. With this milestone, Verovaccines has transformed into a **product-oriented biopharma company** with a validated regulatory framework for subsequent developments. The positive opinion confirms that future vaccine products based on the same platform can be developed **faster, at lower cost, and with reduced risk**.

Dr. Hanjo Hennemann, Managing Director and Co-founder of Verovaccines, commented:
"Verovaccines achieved in record time what many biotechs find extremely challenging — to progress a product through all development stages, scale up manufacturing, and establish a complete regulatory path for approval. With VeroBlue-3, we have entered a new phase of intensified product development to expand our portfolio of agile vaccines."

Dr. Ulrike Diesterbeck, DVM, Managing Director, added:
"Achieving regulatory compliance for VeroBlue-3 — from vaccine design to validated safety and efficacy within just 7.5 months — is a strong endorsement of our platform's performance and especially of the team's ability to deliver under industrial conditions."

This new vaccine class will not only address the **multi-billion-euro market of vaccines against fast-mutating pathogens** but also **regional strain diversity** and **replace conventional pathogen-based vaccines** with products offering **improved adaptability, efficacy, and production economics**. VeroBlue-3 thus represents both a proof of concept and a commercial launchpad for Verovaccines' growth trajectory.

Verovaccines is currently **raising funds from investors** to support value-creating **product development, portfolio expansion**, and **accessing underserved markets** within this new vaccine class.

About Verovaccines GmbH

Verovaccines GmbH is a biopharmaceutical company based in Halle, Germany, developing and scaling a unified, platform-based approach to animal vaccines. Its proprietary “Unified Vaccine Platform” enables rapid, standardized, and economical development of high-quality vaccines that can be produced on a single manufacturing platform. By bridging scientific innovation and industrial efficiency, Verovaccines aims to redefine vaccine development in global animal health.

For investor and media inquiries:

Verovaccines GmbH
Bluecherstrasse 26, 06120 Halle (Saale), Germany
Email: info@verovaccines.com
Website: https://verovaccines.com/